GHK-Cu and Hormonal Contraceptives: What the Evidence Actually Shows

What Is GHK-Cu and How Does It Work?

GHK-Cu is a naturally occurring copper-binding tripeptide (glycine-histidine-lysine complexed with Cu²⁺) first isolated from human plasma by Pickart in 1973. It is present in plasma at roughly 200 ng/mL in young adults, falling to approximately 80 ng/mL by age 60. In clinical use today it appears most often as a compounded topical serum or subcutaneous injection for tissue repair, wound healing, and skin rejuvenation, dispensed under 503A compounding pharmacy rules rather than an FDA-approved new drug application.

Mechanism of Action

The peptide binds free copper and shuttles it into cells via interaction with the copper transporter CTR1. Once internalized, Cu²⁺ activates lysyl oxidase, superoxide dismutase (SOD1 and SOD3), and several collagen-crosslinking enzymes. A 2018 review in Biomolecules confirmed that GHK-Cu upregulates at least 31 genes tied to collagen synthesis and tissue remodeling while downregulating inflammatory pathways, including NF-κB signaling.

Pharmacokinetics: Topical vs. Systemic Routes

Route of administration matters enormously for any interaction analysis. Topical GHK-Cu penetrates the stratum corneum but bioavailability remains low; one ex-vivo skin-penetration study found less than 1% of applied copper peptide reaches the dermal vasculature. Subcutaneous injection produces measurable plasma copper elevations, making systemic interaction concerns more relevant for patients on injectable peptide protocols than for those using a cosmetic serum.

How Hormonal Contraceptives Change Copper Physiology

Oral contraceptives (OCs) containing ethinyl estradiol raise serum copper through a well-characterized mechanism. Estrogen stimulates hepatic synthesis of ceruloplasmin, the primary copper-transport glycoprotein. A study published in Contraception documented mean serum copper increases of 20 to 30% in women starting combined OCs, with ceruloplasmin rising proportionally.

Estrogen Dose and Copper Elevation

The magnitude of copper elevation correlates with estrogen dose. High-dose ethinyl estradiol formulations (35 to 50 mcg) produce larger ceruloplasmin spikes than low-dose pills (10 to 20 mcg ethinyl estradiol). Progestin-only pills, the hormonal IUD (levonorgestrel 52 mg, e.g., Mirena), the implant (etonogestrel 68 mg, Nexplanon), and the hormonal patch (norelgestromin/ethinyl estradiol, Xulane) show a smaller or negligible copper effect because systemic estrogen exposure is lower or absent. The FDA prescribing information for Mirena makes no mention of serum copper effects, consistent with its primarily local action.

Copper IUD: A Separate Category

The copper IUD (ParaGard, 380 mm² of exposed copper) releases approximately 50 mcg of ionic copper per day locally in the uterus. Systemic copper absorption from ParaGard is small but measurable; a 1994 study in Contraception found serum copper increased by only 5 to 10% above baseline in ParaGard users, far less than with OCs. Women using ParaGard alongside systemic GHK-Cu peptide carry a slightly different risk profile than OC users, because the copper source in their case is already elemental.

The Pharmacokinetic Interaction Question: CYP Enzymes and P-Glycoprotein

This section addresses the most clinically direct question: does GHK-Cu affect the enzymes that metabolize estrogen and progestins, or vice versa?

CYP3A4 and Ethinyl Estradiol Metabolism

Ethinyl estradiol is metabolized primarily by CYP3A4, with secondary contributions from CYP2C9 and intestinal P-glycoprotein (P-gp) efflux. Drugs that induce CYP3A4 (rifampicin, carbamazepine, St. John's Wort) reduce ethinyl estradiol AUC by 40 to 80%, causing contraceptive failure. Drugs that inhibit CYP3A4 (fluconazole, certain HIV antiretrovirals) can raise ethinyl estradiol exposure and increase estrogen-related adverse effects.

GHK-Cu is a small tripeptide, not a xenobiotic processed by CYP enzymes in any meaningful way. No in-vitro or in-vivo study available through PubMed as of January 2025 has demonstrated GHK-Cu inhibition or induction of CYP3A4, CYP2C9, CYP1A2, or P-gp. The peptide's molecular weight (340 Da as the copper complex) and rapid hydrolysis in plasma make it an unlikely candidate for cytochrome modulation.

Progestin Metabolism: A Similar Picture

Progestins used in hormonal contraceptives (levonorgestrel, desogestrel, norgestimate, drospirenone, etonogestrel) are also predominantly CYP3A4 substrates. The same absence of GHK-Cu CYP data applies. Until a dedicated in-vitro hepatic microsome study is published, clinicians should note the data gap rather than assume safety.

Pharmacodynamic Overlap: Free Copper Load

The one meaningful pharmacodynamic concern is additive copper loading. Women on high-estrogen OCs already carry elevated serum copper. Subcutaneous GHK-Cu introduces additional chelated Cu²⁺. Free (non-ceruloplasmin-bound) copper is the fraction most associated with oxidative stress; a landmark paper in Free Radical Biology and Medicine established that free copper catalyzes hydroxyl radical generation via Fenton-type chemistry. If ceruloplasmin binding capacity is saturated, free copper rises. Whether typical GHK-Cu doses saturate ceruloplasmin in OC users is unknown, but the mechanism is biologically coherent.

Severity Classification and Clinical Risk Stratification

No established DDI database (Lexicomp, Micromedex, Drugs.com) lists a GHK-Cu/hormonal contraceptive interaction as of January 2025, because GHK-Cu is not classified as a drug in those systems. Applying a standard pharmacovigilance severity scale requires clinical judgment:

Low Risk: Topical GHK-Cu Plus Any Hormonal Contraceptive

Women using GHK-Cu as a topical cosmetic serum (concentrations typically 0.1 to 2%) alongside any hormonal contraceptive carry the lowest risk profile. Systemic copper absorption from topical application is negligible. No dose adjustment of the contraceptive is warranted, and no monitoring beyond routine clinical care is recommended.

Moderate Consideration: Subcutaneous GHK-Cu Plus High-Estrogen OC

A woman injecting compounded GHK-Cu subcutaneously (doses range from 1 to 3 mg per session in clinical practice) while taking a 30 to 35 mcg ethinyl estradiol combined OC faces additive copper load. A baseline serum copper and ceruloplasmin level before starting systemic peptide therapy is a reasonable precaution. The normal reference range for serum copper in adult women is 70 to 140 mcg/dL per NIH clinical reference data. Values above 140 mcg/dL in this context warrant dose review.

Elevated Attention: Subcutaneous GHK-Cu Plus Copper IUD

A patient using systemic GHK-Cu injections who also has a copper IUD (ParaGard) has two exogenous copper sources simultaneously. Although the absolute amounts are small, periodic serum copper monitoring every 6 months is a defensible protocol given the absence of safety data in this combination.

What the Literature Does (and Does Not) Say

GHK-Cu has a respectable basic-science record. The 2018 Biomolecules review cited above analyzed 50+ published studies on GHK-Cu's biological activity. A 2015 study in PLoS ONE demonstrated GHK-Cu's ability to activate TGF-beta pathways and increase collagen type I production in fibroblasts. A 2012 paper in Analytical and Bioanalytical Chemistry characterized the copper-binding stoichiometry of the GHK complex in physiologic pH.

None of these papers examined hormonal contraceptive co-administration. The honest clinical answer is that no controlled human trial has studied this combination. That is a data gap, not implicit safety clearance.

The Endocrine Society's 2015 guidelines on copper metabolism (academic.oup.com) note that estrogen-driven ceruloplasmin elevation is "a pharmacological rather than pathological phenomenon in most OC users" and does not typically require clinical intervention. That framing is useful context, but it was not written with GHK-Cu co-administration in mind.

Drug Interaction Considerations by Contraceptive Type

| Contraceptive | Estrogen Component | Copper Effect | GHK-Cu Concern Level | |---|---|---|---| | Combined OC (35 mcg EE) | Ethinyl estradiol 35 mcg | +20 to 30% serum Cu | Moderate (systemic GHK-Cu) | | Combined OC (20 mcg EE) | Ethinyl estradiol 20 mcg | +10 to 20% serum Cu | Low-moderate | | Progestin-only pill | None | Negligible | Low | | Hormonal IUD (Mirena) | None systemic | Negligible | Low | | Implant (Nexplanon) | None | Negligible | Low | | Patch (Xulane) | Ethinyl estradiol ~35 mcg/day | +15 to 25% serum Cu | Moderate (systemic GHK-Cu) | | Copper IUD (ParaGard) | None | +5 to 10% serum Cu (local Cu release) | Moderate-elevated (systemic GHK-Cu) |

Patient Counseling Points

Patients combining GHK-Cu with hormonal contraceptives should know several things.

First, topical GHK-Cu products sold as cosmetics carry negligible systemic copper exposure and do not require any contraceptive adjustment. Second, if a patient is using compounded injectable GHK-Cu through a 503A pharmacy, the prescribing clinician should document the hormonal contraceptive being used and establish a baseline serum copper. Third, symptoms of copper excess (nausea, abdominal cramping, liver enzyme elevation) are non-specific but worth flagging if they emerge during concurrent use. The CDC's copper toxicity reference lists GI symptoms as the earliest indicators of elevated free-copper exposure. Fourth, contraceptive efficacy is not expected to be compromised by GHK-Cu, because the peptide has no known CYP3A4 activity. Patients should not discontinue their contraceptive out of interaction concern.

The American College of Obstetricians and Gynecologists (ACOG) does not yet address peptide co-administration in its contraceptive guidance (acog.org), which reflects the recency of compounded peptide use rather than established safety.

Monitoring Protocol for Clinicians

Clinicians prescribing or recommending systemic GHK-Cu to patients on hormonal contraceptives may consider the following framework, adapted from standard copper-overload monitoring principles:

Baseline Assessment

Order serum copper and ceruloplasmin before starting subcutaneous GHK-Cu in any patient on a combined OC or estrogen-containing contraceptive patch. A result above 140 mcg/dL (normal upper limit for women per NIH biochemistry references) should prompt a discussion about dose timing or method change before initiating peptide therapy.

Ongoing Monitoring

Recheck serum copper at 3 months after initiating GHK-Cu injections, then every 6 months if levels remain within range. Liver function tests (ALT, AST) are reasonable additions given copper's hepatic metabolism, particularly in patients with any history of liver disease. Wilson's disease must be excluded before initiating any exogenous copper-containing therapy; the standard screening test is serum ceruloplasmin below 20 mg/dL paired with a 24-hour urine copper above 100 mcg/day per AASLD guidelines available via PubMed.

Dose Considerations

No published dose-adjustment algorithm exists for GHK-Cu in OC users. A conservative approach: start at the lower end of the clinical range (1 mg subcutaneous per session, 2 to 3 times per week) and titrate only after confirming serum copper remains below 140 mcg/dL at the 3-month check.

What Remains Unknown

The field of peptide therapeutics is moving faster than the clinical trials literature. Key unanswered questions include:

• Whether supraphysiologic GHK-Cu dosing saturates ceruloplasmin binding in OC users.
• Whether free-copper elevation from combined GHK-Cu/OC use produces measurable oxidative stress markers (e.g., 8-OHdG, F2-isoprostanes).
• Whether the ceruloplasmin elevation seen with OCs actually reduces or increases GHK-Cu's biological activity by altering free Cu²⁺ availability.
• Whether any CYP enzyme modulation occurs at doses above those currently used clinically.

A properly designed pharmacokinetic crossover trial (GHK-Cu 2 mg subcutaneous vs. Placebo, in combined OC users vs. Non-users, measuring serum copper, ceruloplasmin, free copper, and ethinyl estradiol AUC) would resolve the core questions. No such trial has been registered on ClinicalTrials.gov as of this writing.

Summary of the Evidence Base

The published record on GHK-Cu spans basic science reliably, with peer-reviewed studies confirming its copper-chaperoning, collagen-stimulating, and anti-inflammatory activity in cell culture and animal models. What it does not contain is any human pharmacokinetic trial examining GHK-Cu co-administration with ethinyl estradiol-containing or progestin-only contraceptives. Hormonal contraceptives raise serum copper through ceruloplasmin upregulation, a well-documented effect published in Contraception and replicated in multiple cohorts. GHK-Cu introduces additional copper into the system. For topical users, the systemic dose is negligible. For subcutaneous users on high-estrogen OCs, a baseline and periodic serum copper level is the most defensible single monitoring step currently available.

Order serum copper and ceruloplasmin before starting any systemic GHK-Cu protocol in a patient taking a combined oral contraceptive containing 30 mcg or more of ethinyl estradiol.